Effects of Combined MAO-B Inhibitors and Levodopa vs. Monotherapy in Parkinson’s Disease

Frontiers in Aging Neuroscience - Switzerland
doi 10.3389/fnagi.2014.00180
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Inflammation in Parkinson’s Disease: Role of Glucocorticoids

Frontiers in Neuroanatomy
AnatomyNeuroscienceCellularMolecular Neuroscience
2015English

Slowing of EEG Background Activity in Parkinson’s and Alzheimer’s Disease With Early Cognitive Dysfunction

Frontiers in Aging Neuroscience
AgingCognitive Neuroscience
2014English

Hedonic Deficits in Parkinson’s Disease: Is Consummatory Anhedonia Specific?

Frontiers in Neurology
Neurology
2014English

Parkinson’s Disease-Implicated Kinases in the Brain; Insights Into Disease Pathogenesis

Frontiers in Molecular Neuroscience
Molecular NeuroscienceMolecular BiologyCellular
2014English

Rational Pharmacological Approaches for Cognitive Dysfunction and Depression in Parkinson’s Disease

Frontiers in Neurology
Neurology
2015English

Dopamine and the Biology of Creativity: Lessons From Parkinson’s Disease

Frontiers in Neurology
Neurology
2014English

The Correlation Between Osteoporosis Occurrences in Both Schizophrenia and Parkinson’s Disease

Frontiers in Neurology
Neurology
2014English

Will Crystal Parkin Help in Understanding the Future of Parkinson’s Disease?

Frontiers in Neurology
Neurology
2015English

Post-Cueing Deficits With Maintained Cueing Benefits in Patients With Parkinson’s Disease Dementia

Frontiers in Neurology
Neurology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy